Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2023Scientific ReportsOpen Access

SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

TMThomas A. MavrakanasGeneral CardiologyMTMichael A. TsoukasRoyal Victoria HospitalJBJames M. BrophyGeneral Cardiology

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mavrakanas et al. (2023) studied this question.

synapsesocial.com/papers/6a760546881b59604d613a3ahttps://doi.org/10.1038/s41598-023-42989-z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Plea for routinely presenting prediction intervals in meta-analysis2016 · 2,298 citations
  2. 2Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function2020 · 286 citations
  3. 3Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial2020 · 180 citations
  4. 4Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction2022 · 132 citations
  5. 5Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy2019 · 6,236 citations